Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has announced its participation in four major investor conferences in September 2025.
The company will engage in fireside chats at the Citi Biopharma Back to School Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 9), and Stifel Virtual Immunology and Inflammation Forum (Sept 15). All presentations will be accessible via live webcast on the company's website, with replays available afterward.
Positive
- None.
Negative
- None.
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Citi 2025 Biopharma Back to School Conference in Boston, MA on September 3 at 10:30 a.m. ET;
- Wells Fargo 2025 Healthcare Conference in Boston, MA on September 4 at 9:30 a.m. ET;
- Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 9 at 12:20 p.m. ET; and
- Stifel 2025 Virtual Immunology and Inflammation Forum on September 15 at 12:30 p.m. ET.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Availability of Other Information About Kymera Therapeutics
For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When is Kymera Therapeutics (KYMR) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Kymera Therapeutics' (KYMR) September 2025 conference presentations?
What is the schedule for Kymera Therapeutics' (KYMR) September 2025 investor conferences?
What type of medicines is Kymera Therapeutics (KYMR) developing?
